¡ã ÇãÁØ¿µ ±³¼ö
ÇѾç´ëÇб³±¸¸®º´¿ø Ç÷¾×Á¾¾ç³»°ú ÇãÁØ¿µ ±³¼ö°¡ ´ëÇÑÁ¾¾ç³»°úÇÐȸ¿¡¼ ÀÓ»ó ¾Ï ¿¬±¸ ºÐ¾ßÀÇ ³í¹®À¸·Î ¡®2020³â Çѱ¹¾ÏÇмúÀç´Ü Çмú»ó¡¯À» ¼ö»óÇß´Ù.
Çã ±³¼ö´Â Oncoimmunology (IF=5.33)¿¡ °ÔÀçµÈ 'Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment' ¶ó´Â Á¦¸ñÀÇ ³í¹®À¸·Î À̹ø »óÀ» ¼ö»óÇÏ¿´´Ù.
ÀÌ¿Í °ü·Ã Çã ±³¼ö´Â ¡°¸é¿ªÇ×¾ÏÁ¦ Åõ¿© ÀüÈÄ T¸²ÇÁ±¸ÀÇ º¯ÈÆÐÅÏÀ» ÅëÇÏ¿© ¸é¿ªÇ×¾ÏÁ¦ ºÎÀÛ¿ëÀÇ ±âÀüÀ» ¹àÈ÷°íÀÚ ÇÑ ³í¹®À¸·Î, À̹ø ¿¬±¸ °á°ú¸¦ Åä´ë·Î ¸é¿ªÇ×¾ÏÁ¦ °ü·Ã ºÎÀÛ¿ëÀ» Ä¡·áÇÏ´Â ±Ù°Å¸¦ Á¦½ÃÇÏ°íÀÚ ÇÑ´Ù¡±°í ¼Ò°¨À» ¹àÇû´Ù.
ÇãÁØ¿µ ±³¼ö´Â ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐÀ» Á¹¾÷ÇÏ°í, °æÈñ´ë ´ëÇпø¿¡¼ ¼®»ç¿Í ¼º±Õ°ü´ë ´ëÇпø ¹Ú»ç ¼ö·á ¹× »ï¼º¼¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú ÀÓ»ó°»ç¸¦ ¼ö·áÇÏ¿´À¸¸ç, ´ëÇѳ»°úÇÐȸ, ´ëÇѾÏÇÐȸ, ´ëÇÑÇ÷¾×ÇÐȸ, ´ëÇÑÁ¾¾ç³»°úÇÐȸ, ´ëÇÑÇ׾Ͽä¹ý¿¬±¸È¸, ¹Ì±¹¾Ï¿¬±¸ÇÐȸ (American Association for Cancer Research, AACR) µî¿¡¼ È°¹ßÇÑ È°µ¿À» ÇÏ°í ÀÖ´Ù.